Inhibitor development in patients with hemophilia: an overview.
Leissinger
Cindy A
CA
Tulane University, New Orleans, LA 70112, USA. cleissi@tulane.edu
D000906:Antibodies / Q000032:analysis; D019774:Blood Coagulation Factor Inhibitors / Q000191:economics / Q000276:immunology*; D001779:Blood Coagulation Factors / Q000191:economics / Q000494:pharmacology; D005164:Factor IX / Q000037:antagonists & inhibitors / Q000276:immunology*; D005169:Factor VIII / Q000037:antagonists & inhibitors / Q000276:immunology; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology*; D006470:Hemorrhage / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007108:Immune Tolerance; D017211:Treatment Failure
D000906:Antibodies; D019774:Blood Coagulation Factor Inhibitors; D001779:Blood Coagulation Factors; D005169:Factor VIII; D005164:Factor IX; C065655:anti-inhibitor coagulant complex